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Abstract: Carcinoembryonic antigen (CEA), highly expressed in many cancer types, is an important target for cancer 
diagnosis and therapy. Radionuclide-based imaging techniques (gamma camera, single photon emission computed tomog-
raphy [SPECT] and positron emission tomography [PET]) have been extensively explored for CEA-targeted cancer imag-
ing both preclinically and clinically. Brieﬂ  y, these studies can be divided into three major categories: antibody-based, 
antibody fragment-based and pretargeted imaging. Radiolabeled anti-CEA antibodies, reported the earliest among the three 
categories, typically gave suboptimal tumor contrast due to the prolonged circulation life time of intact antibodies. 
Subsequently, a number of engineered anti-CEA antibody fragments (e.g. Fab’, scFv, minibody, diabody and scFv-Fc) have 
been labeled with a variety of radioisotopes for CEA imaging, many of which have entered clinical investigation. CEA-Scan 
(a 
99mTc-labeled anti-CEA Fab’ fragment) has already been approved by the United States Food and Drug Administration 
for cancer imaging. Meanwhile, pretargeting strategies have also been developed for CEA imaging which can give much 
better tumor contrast than the other two methods, if the system is designed properly. In this review article, we will sum-
marize the current state-of-the-art of radionuclide-based cancer imaging targeting CEA. Generally, isotopes with short 
half-lives (e.g. 
18F and 
99mTc) are more suitable for labeling small engineered antibody fragments while the isotopes with 
longer half-lives (e.g. 
123I and 
111In) are needed for antibody labeling to match its relatively long circulation half-life. With 
further improvement in tumor targeting efﬁ  cacy and radiolabeling strategies, novel CEA-targeted agents may play an 
important role in cancer patient management, paving the way to “personalized medicine”.
Keywords: carcinoembryonic antigen, single photon emission computed tomography (SPECT), positron emission tomog-
raphy (PET), antibody, antibody fragment, pretargeting
Introduction
Carcinoembryonic antigen (CEA), a complex and highly glycosylated macromolecule, contains 
approximately 50% carbohydrate with a molecular weight of around 200 kDa. Normally expressed 
during the development of the fetal gut, it is also a well-established tumor-associated antigen highly 
expressed in colorectal carcinoma and frequently elevated in adenocarcinomas of the lung, breast, other 
gastrointestinal organs and the ovaries (Goldstein and Mitchell, 2005; Schneider, 2006; Ugrinska et al. 
2002). In 1981, the National Institutes of Health (NIH) announced that monitoring CEA expression was 
the best available non-invasive technique for the detection of recurrences in patients with a history of 
colorectal cancer (1981). Subsequently, CEA measurement has been widely used in the follow-up of 
patients after resection of colorectal cancer. Because its expression level in normal tissues is quite low, 
CEA is also a suitable target for cancer intervention (Goldenberg et al. 1978).
Molecular imaging refers to the characterization and measurement of biological processes at the 
molecular level (Mankoff, 2007; Massoud and Gambhir, 2003). It takes advantage of traditional diag-
nostic imaging techniques and introduces molecular probes to measure the expression of indicative 
molecular markers at different stages of diseases. The most frequently used molecular imaging modal-
ities include optical bioluminescence, optical ﬂ  uorescence, targeted ultrasound, molecular magnetic 
resonance imaging, single photon emission computed tomography (SPECT) and positron emission 
tomography (PET). Recently, optical imaging has been employed for intra-operative or non-invasive 
imaging of CEA-positive tumors (Kaushal et al. 2008; Venisnik et al. 2007). Comparing to optical 
imaging, radionuclide-based imaging techniques are more advantageous in that they are very sensitive 436
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and quantitative with no tissue penetration limit, 
hence more suitable for clinical translation. Clini-
cally, SPECT and PET has been widely used over 
the last several decades in cancer patient manage-
ment, including diagnosis, staging and treatment 
monitoring (Kelloff et al. 2005). In this review, we 
will summarize the current state-of-the-art radio-
nuclide-based cancer imaging targeting CEA.
SPECT and Gamma Camera Imaging
SPECT imaging detects gamma rays (Kjaer, 2006; 
Peremans et al. 2005). A collimator is used to only 
allow the emitted gamma photon to travel along 
certain directions to reach the detector, which 
ensures that the position on the detector accurately 
represents the source of the gamma ray. The gamma 
camera can be used in planar imaging to obtain 
2-D images, or in SPECT imaging to obtain 3-D 
images.
Because of the use of lead collimators to deﬁ  ne 
the angle of incidence, SPECT imaging has a very 
low detection efﬁ  ciency (10
−4 times the emitted 
number of gamma rays) (Chatziioannou, 2005). 
Common radioisotopes used for SPECT imaging 
are 
99mTc (t1/2: 6.0 h), 
111In (t1/2: 2.8 d), 
123I (t1/2: 13.2 h) 
and 
131I (t1/2: 8.0 d). SPECT and gamma camera 
imaging is currently the most frequently used 
modality for CEA imaging. Based on the targeting 
ligands used, they can be broadly divided into the 
following categories: antibody-based, antibody 
fragment-based and pretargeted imaging.
Antibody-based imaging
The use of radiolabeled antibodies for tumor imag-
ing and therapy continues to be an active area of 
research. Immunoscintigraphy can be an adequate 
diagnostic tool for colorectal cancer, especially in 
recurrences. CEA imaging using radiolabeled 
intact antibodies dated back to the early 1980s 
(Berche et al. 1982). In 1982, a 
131I-labeled mono-
clonal antibody (mAb) against CEA was used 
clinically for detecting gastrointestinal and medul-
lary thyroid cancers. The results were very prom-
ising: SPECT imaging detected 16 out of 17 tumor 
sites (94%) while only 9 out of 21 (43%) tumor 
sites were identiﬁ  ed by rectilinear scintigraphy 
(Berche et al. 1982). This pioneering report repre-
sents a very important ﬁ  rst step for antibody-based 
imaging of CEA expression in the clinic.
Subsequently, SPECT imaging with a number of 
antibodies against CEA was reported. For example, 
111In-labeled ZCE-025 (an anti-CEA mAb that does 
not react with normal granulocyte glycoproteins) 
was investigated in several studies for the detection 
of primary, metastatic, or recurrent colorectal car-
cinomas (Abdel-Nabi et al. 1988; Abdel-Nabi et al. 
1991; Kramer et al. 1988; Patt et al. 1988; Patt 
et al. 1990). Imaging in patients with rising CEA 
levels successfully detected metastatic colorectal 
cancer that could not be detected by other methods, 
therefore changing patient management in many 
cases. Interestingly, 1 mg of 
111In-labeled ZCE-025 
co-infused with 39 mg of unlabeled antibody 
achieved much better performance in detecting 
colorectal cancer, particularly for liver metastases, 
than 
111In-labeled ZCE-025 itself (Patt et al. 1988). 
Although the exact mechanism(s) for this effect is 
unknown, partial “blocking” caused by the unla-
beled antibody may have changed the biodistribu-
tion of the radiopharmaceutical.
In these reports, there was no correlation 
between serum levels of CEA and lesion detect-
ability with mAb-based imaging. For example, the 
discrepancy between serum CEA levels and tissue 
CEA expression in breast cancer patients is well 
known. Although immunohistochemistry shows 
positive CEA expression in 70%–90% of the cases 
in breast cancer, the serum CEA levels are often 
within the normal range (Lind et al. 1991b). In 
1991, immunoscintigraphy with a 
111In-labeled anti-
CEA mAb (F023C5i) was performed in 66 patients 
suspected for primary lung cancer (Grifﬁ  n et al. 
1991). A sensitivity of 90%, speciﬁ  city of 45% and 
accuracy of 85% was achieved. SPECT imaging 
delineated the lesions better than planar gamma 
camera imaging in each patient, although it did 
not reveal any new lesions not seen in planar 
imaging.
Radioiodine and 
111In has not been widely used 
for labeling anti-CEA antibodies due to the high 
cost, limited availability and relatively poor image 
quality with most gamma cameras (Hansen et al. 
1990; Riva et al. 1988). 
111In is relatively difﬁ  cult 
to conjugate to antibodies. Moreover, it usually has 
considerable accumulation in the reticuloendothe-
lial organs such as the liver, often a major site for 
tumor metastasis, which signiﬁ  cantly limits its 
potential in cancer imaging.
99mTc is the most widely used isotope for 
SPECT imaging (Banerjee et al. 2001; Mease and 
Lambert, 2001). It emits readily detectable 140 keV 
gamma rays, about the same energy as that used 
in conventional diagnostic X-ray instrument. 437
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The short half-life of 
99mTc allows for rapid 
scanning procedures and at the same time keeping 
the total radiation exposure to the patient low. 
Most importantly, it is readily available with a very 
low cost. 
99mTc has been used to label many anti-
CEA antibodies (e.g. BW431/26, IMMU-4 and 
88BV59) and used in clinical studies for the detec-
tion of colorectal, breast and lung cancer (Barzen 
et al. 1992; Baum et al. 1989; Behr et al. 1995; 
Fraile et al. 1991; Gonzalez et al. 1991; Kairemo 
et al. 1993; Lacic et al. 1999; Lind et al. 1989; 
Lind et al. 1991a; Lind et al. 1991b; Oriuchi et al. 
1995; Patt et al. 1994; Seraﬁ  ni et al. 1998; Sirisriro 
et al. 1996; Stomper et al. 1995; Takenoshita et al. 
1995). It was concluded that 
99mTc-based immu-
noSPECT is a suitable method for cancer diagnosis, 
especially for recurrences. For primary breast 
cancer, 
99mTc-based immunoSPECT has achieved 
83% sensitivity and 69% speciﬁ  city (Lind et al. 
1991b). In primary colorectal cancer patients, the 
lesions can be scintigraphically detected with a 
sensitivity of 83% and a speciﬁ  city of 100%. In 
recurrent colorectal cancer, a sensitivity of 77% 
and speciﬁ  city of 88% was reported (Hach et al. 
1992). In 1998, a 
99mTc-labeled fully humanized 
mAb 88BV59 was evaluated in a phase III clinical 
trial to image recurrent, metastatic, or occult 
colorectal cancer (Seraﬁ  ni et al. 1998). The trial 
was a success in that it can provide important and 
accurate information about the presence and 
location of malignant lesions in patients which 
could not be detected by computed tomography 
(CT) scans.
Many studies have conﬁ  rmed that immunoscin-
tigraphy with radio-labeled anti-CEA mAbs is 
superior to CT for the detection of pelvic and 
extrahepatic abdominal recurrences of colorectal 
cancer, while CT is more sensitive in detecting 
liver and lung metastases. The major reason for 
this phenomenon is that the blood pool activity 
typically masks the lung lesion due to the long 
circulation half-lives of the mAbs and the liver 
uptake of the mAbs can overshadow the uptake in 
liver metastases. Besides the limited use in detect-
ing lung and hepatic lesions, the prolonged 
persistence of the radiolabeled antibody in the 
circulation can also lead to high background signal. 
Traditionally, many mAbs are expressed in animals, 
such as mice, which can induce human anti-mouse 
antibody (HAMA) activity in many patients 
(Nussbaum and Roth, 2000; Zbar et al. 2005). 
Therefore, researchers have explored the use of 
antibody fragments (Fig. 1) for CEA imaging 
which may have better tumor targeting and 
pharmacokinetic properties.
Fab’ fragment-based imaging
Fab’ fragments of anti-CEA antibodies have been 
tested for cancer imaging in the early 1990s. 
Successful imaging of CEA-positive carcinomas 
within 2 h of intravenous (i.v.) injection of a 
99mTc-labeled anti-CEA Fab’ fragment was reported 
(Goldenberg et al. 1990). Rapid tumor targeting, 
within a few hours after administration and fast 
clearance from the blood and normal organs of the 
Fab’ fragments (blood half-life: 13.2 h) permitted 
the use of short-lived radionuclides such as 
123I and 
99mTc. Scanning at 2–5 h post-injection (p.i.) of the 
99mTc-labeled Fab’ fragment gave a sensitivity of 
95% and an accuracy of 94% on a tumor site basis. 
The radiolabeled Fab’ fragment also revealed a high 
number of lesions not detectable by other radio-
logical methods, of which 21% were subsequently 
conﬁ  rmed as malignant lesions within a 11-month 
follow-up period. The smallest tumors identiﬁ  ed 
were below 0.5 cm in diameter. This report demon-
strated that the 
99mTc-labeled Fab’ fragment, which 
could be prepared by 1-step direct labeling, appears 
to be the method of choice for rapid and accurate 
detection of cancer. Although a 
123I-labeled Fab’ 
fragment gave slightly better results (sensitivity of 
96% and accuracy of 94%) than the 
99mTc-labeled 
version, the limited availability and high cost of 
123I limited its potential in clinical use.
lgG
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Figure 1. Intact antibodies and a variety of antibody fragments have 
been explored for CEA-targeted cancer imaging.438
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After this initial report, a number of anti-CEA 
Fab’ fragments with various radiolabels have been 
used in the detection of metastatic and recurrent 
colorectal carcinomas (Fig. 2) (Erb and Nabi, 2000; 
Fuster et al. 2003; Ghesani et al. 2003; Goldenberg 
et al. 1997; Hladik et al. 2001; Moffat et al. 1996; 
Sanidas et al. 2003; Willkomm et al. 2000). To 
assess the performance and potential clinical 
impact of this Fab’ fragment-based tracer, a study 
in 210 presurgical patients with advanced recurrent 
or metastatic colorectal carcinomas was conducted 
(Moffat et al. 1996). Imaging with conventional 
diagnostic modalities, as well as surgery and histol-
ogy, was also performed to validate the imaging 
results. It was found that the sensitivity of the Fab’ 
fragment-based SPECT imaging was superior to 
that of conventional modalities in the extrahepatic 
abdomen (55% vs 32%) and the pelvis (69% vs 
48%) and the Fab’ fragment-based ﬁ  ndings com-
plemented those of conventional modalities in the 
liver. Among the patients with known disease, the 
positive predictive value was signiﬁ  cantly higher 
when both modalities were positive (98%) than 
with each modality alone (∼70%), thus potentially 
avoiding the need for histologic conﬁ  rmation when 
both tests are positive. Less than 5% of the patients 
developed HAMA reaction to the radiolabeled 
anti-CEA Fab’ fragment after a single injection. 
Taken together, radiolabeled Fab’ fragment can 
afford high-quality, same day cancer detection with 
an inexpensive and readily available radionuclide. 
It can also add clinically signiﬁ  cant information in 
assessing the extent and location of diseases in 
colorectal cancer patients, usually without inducing 
A
B
Figure 2. SPECT imaging with CEA-Scan. A) Normal biodistribution of CEA-Scan at 4 h post-injection. Anterior planar images of the chest, 
abdomen and pelvis are shown. B) Planar anterior pelvis imaging at 5 h (left) and 24 h (right) post-injection clearly delineated the lesion. 
Arrows point to the tumor which was close to the bladder. Adapted from (Erb and Nabi, 2000).439
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a HAMA response. In 1996, a 
99mTc-labeled 
anti-CEA Fab’ fragment (arcitumomab; CEA-Scan; 
Immunomedics, Inc.) was approved by the United 
States Food and Drug Administration (FDA) for 
colorectal cancer imaging. Subsequently, CEA-
Scan has also been applied for detecting other 
CEA-positive cancers such as breast cancer, med-
ullary thyroid cancer and lung cancer (Goldenberg, 
1997; Goldenberg et al. 1997; Goldenberg and 
Nabi, 1999; Goldenberg and Wegener, 1997; 
Malamitsi et al. 2002; Sanidas et al. 2003).
In 2000, a study was conducted to compare the 
imaging efficiency of 
18F-fluorodeoxyglucose 
(
18F-FDG; t1/2: 109.8 min) PET, the “gold standard” 
of clinical cancer imaging (Gambhir et al. 2001), 
with CEA-Scan SPECT in colorectal cancer 
patients (Willkomm et al. 2000). Patients previ-
ously treated for colorectal carcinoma and were 
suspected for recurrence, were examined by both 
imaging modalities. CEA-Scan correctly detected 
8 of 9 local recurrences, whereas 
18F-FDG PET 
was able to detect all 9 cases with 1 case being 
false-positive. Liver metastases were conﬁ  rmed in 
9 patients by 
18F-FDG PET but in only 1 patient 
by CEA-Scan SPECT. Two cases with lymph node 
metastases and 2 cases with lung metastases were 
correctly identified by 
18F-FDG PET, none of 
which detected by CEA-Scan SPECT. Lastly, bone 
metastases were identiﬁ  ed in 1 patient by 
18F-FDG 
PET but not by CEA-Scan SPECT, whereas bone 
marrow inﬁ  ltration was diagnosed by both imaging 
modalities. These results indicated that 
18F-FDG 
PET and CEA-Scan SPECT are both suitable for 
detecting local recurrences of colorectal carci-
noma. However, 
18F-FDG PET is clearly superior 
in the detection of distant metastases (e.g. in the 
liver, bone and lung) and lymph node metastases 
(Libutti et al. 2001).
The absolute level of tumor uptake is typically 
higher for radiolabeled mAbs than the radiolabeled 
Fab’ fragments. However, lesions with good vas-
cularization, vascular permeability and antigen 
accessibility can be detected earlier and with higher 
sensitivity by radiolabeled Fab’ fragments than 
intact mAbs, primarily due to faster background 
clearance despite the lower absolute tumor uptake. 
On the other hand, the smaller size and faster clear-
ance of Fab’ fragments also brings some problems, 
most notably the prominent renal uptake. To solve 
this problem, cationic amino acids (such as lysine 
and arginine) and their derivatives have been used 
to reduce the renal uptake of various tracers in 
animals (Behr et al. 1996). Successful renal uptake 
reduction in patients, injected with 
99mTc-labeled 
anti-CEA Fab’ fragments, was also achieved using 
amino acid infusion (Behr et al. 1996). Meanwhile, 
many other anti-CEA antibody fragments have also 
been explored for better imaging results.
Single chain Fv-based imaging
A single chain Fv (scFv; 25 kDa) fragment is 
consisted of the variable heavy (VH) and light (VL) 
regions of an antibody, linked with a short peptide 
sequence (Huston et al. 1988). ScFv fragments can 
be rapidly cleared from the blood (half-life less 
than a few hours), which can give very high tumor-
to-blood ratio. They also have good penetration 
into solid tumors because they are less than one-
ﬁ  fth the size of an intact mAb. Another advantage 
of scFv fragments is the reduced immunogenicity, 
because of the elimination of amino acid residues 
not involved in antigen binding.
In 1996, a bacteriophage library was used to 
select MFE-23, the ﬁ  rst high-afﬁ  nity scFv directed 
against CEA (Begent et al. 1996). After labeling 
with 
123I, this scFv was tested in normal and 
colorectal carcinoma patients. It exhibited superior 
diagnostic characteristics than conventional imag-
ing modalities, such as CT, in that it can image 
hepatic or abdominal metastases not detectable by 
any other modalities. The high tumor-to-blood 
ratios achieved in this clinical study explained why 
imaging with 
123I-labeled MFE-23 was more sen-
sitive than CT scans. Subsequently, the crystal 
structure of MFE-23 and its intermolecular con-
tacts with CEA was elucidated (Boehm et al. 2000). 
In 2000, MFE-23 was labeled with 
125I (t1/2: 60.1 d) 
for image-guided surgery (Chester et al. 2000; 
Mayer et al. 2000). It was given intravenously 
before surgery and a hand-held gamma-detecting 
probe was used to locate the tumor in the operative 
ﬁ  eld. Thirty-four colorectal carcinoma patients 
(17 primary tumors, 16 liver metastases and 
1 anastomotic recurrence) and 1 patient with liver 
metastases of pancreatic carcinoma received 
125I-labeled MFE-23 at various time points before 
surgery. 
125I-labeled MFE-23 showed good tumor 
localization, with an overall diagnostic accuracy 
of 84% when compared with histology. The short 
time interval between tracer injection and operation, 
the lack of signiﬁ  cant toxicity and the relatively 
simple production in bacteria makes MFE-23 
highly amenable for image-guided surgery.440
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Despite their small size (25 kDa), most of the 
radiolabeled scFvs did not perform well in pre-
clinical and clinical studies because of their poor 
tumor retention (Shively, 2007). The fast blood 
clearance signiﬁ  cantly hampered their potential in 
cancer diagnosis, although the high tumor-to-blood 
ratios would otherwise make them attractive as 
imaging agents. Besides the fast clearance, low 
avidity (due to the monovalency) of scFv fragments 
is another reason why they are not optimal for 
cancer imaging.
To improve the pharmacokinetics of scFv frag-
ments, they were combined with antibody Fc frag-
ments to form scFv-Fc chimeras which contain two 
scFv fragments (∼105 kDa). The behavior of three 
anti-CEA scFv-Fc variants (I253A, H310A and 
H310A/H435Q) with differential serum persis-
tence has been studied for tumor imaging 
(Kenanova et al. 2007). Biodistribution studies in 
CEA-positive tumor-bearing mice revealed that 
the 
111In-labeled I253A fragment with the slowest 
blood clearance (serum half-life: 27.7 h) had the 
highest tumor uptake (44.6 percentage injected 
dose per gram of tissue [%ID/g] at 24 h p.i.), 
whereas the radiometal-labeled H310A/H435Q 
fragment with the most rapid elimination (serum 
half-life: 7.1 h) only had a maximum tumor uptake 
of 28.0%ID/g at 12 h p.i. The H310A fragment 
which has an intermediate serum half-life exhibited 
an intermediate level of tumor uptake. Biodistribu-
tion studies also showed that all three fragments 
were eliminated primarily through the liver and 
the hepatic radioactivity accumulation correlated 
with the rate of tracer clearance. Dosimetry estima-
tion based on 
125I-labeled scFv-Fc fragments sug-
gested that 
131I-labeled H310A/H435Q may be a 
promising candidate for radioimmunotherapy. 
Clearly, bivalent antibody fragments are superior 
for tumor targeting and imaging than the monova-
lent analogs (e.g. Fab’ and scFv) in many aspects. 
Besides scFv-Fc, several other forms of antibody 
fragments have also been explored for CEA-
targeted cancer imaging.
Diabody- and minibody-based imaging
Diabodies are the dimeric forms of scFv with a 
molecular weight of about 55 kDa (Carmichael 
et al. 2003; Li et al. 2006; Perez et al. 2006; Yazaki 
et al. 2001a). Radiolabeled diabodies have shown 
promise as in vivo tumor imaging agents in pre-
clinical studies mainly due to two reasons. First, they 
have high avidity (bivalent) binding to the tumor 
antigens which gives better tumor retention than 
Fab’ or scFv fragments; Second, their intermediate 
size leads to improved tumor-to-blood ratios than 
intact antibodies. Because of their high retention 
and metabolism in the kidneys, it was proposed 
that radioiodine would be a preferred choice for 
diabody labeling since radioiodine can be rapidly 
excreted from the kidney once metabolized 
(Williams et al. 2001). However, the drawback to 
radioiodinated agents is that they may also be 
rapidly metabolized in tissues including the tumor, 
especially if the antigen undergoes internalization 
upon antibody or antibody fragment binding.
Although most anti-CEA antibodies undergo 
negligible internalization, higher tumor uptake and 
persistence was observed for radiometal-labeled 
(e.g. 
111In) anti-CEA antibodies than the radioiodin-
ated analogs (Yazaki et al. 2001b). For radiometal-
labeled antibody fragments, this advantage is 
offset by high kidney retention, likely due to the 
slow excretion of the radiometal-labeled metabo-
lites than the radioiodinated counterparts. There-
fore, poly(ethylene glycol) (PEG) has been 
incorporated to improve the biodistribution of an 
anti-CEA diabody (Li et al. 2006). A number of 
other modiﬁ  cations have also been investigated for 
improving the in vivo kinetics of antibody frag-
ments, such as albumin infusion (Muller et al. 
2007), streptococcal protein G infusion (Stork et al. 
2007), biotinylation (Barat and Wu, 2007) and 
humanization according to its crystal structure 
(Yazaki et al. 2004). When fused with luciferases, 
anti-CEA diabodies have been successfully used 
for the delineation of CEA-positive tumors with 
optical bioluminescence imaging (Venisnik et al. 
2007; Venisnik et al. 2006).
Another type of antibody fragments, termed 
“minibodies”, has also been reported for CEA 
imaging. The chimeric T84.66 minibody is an 
engineered antibody construct (80 kDa) that exhib-
its bivalent binding and sub-nanomolar afﬁ  nity to 
CEA (Wong et al. 2004). In animal models, the 
minibody demonstrated high tumor uptake, similar 
activity as intact antibodies with substantially 
faster clearance rate and superior tumor-to-blood 
ratios than the (Fab’)2 fragment, all of which makes 
it very attractive for further evaluation as an imag-
ing and therapeutic agent (Yazaki et al. 2001b). 
A pilot clinical study was thus undertaken to 
evaluate the biodistribution, pharmacokinetics and 
immunogenicity of 
123I-T84.66 minibody and 441
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determine whether it can target the tumor in 
colorectal cancer patients (Wong et al. 2004). Ten 
patients with biopsy-proven colorectal cancer each 
received 5–10 mCi (∼1 mg) of the 
123I-labeled 
minibody i.v. followed by serial SPECT and/or 
gamma camera scans, as well as blood and urine 
sampling over the next 3 days. Tumor detection 
was achieved with the 
123I-labeled anti-CEA mini-
body in seven of the eight patients who did not 
receive neoadjuvant therapy before surgery. During 
surgery, no tumor was detected in one patient and 
only a 2-mm nodule was seen in another patient. 
Mean serum residence time of the radiolabeled 
minibody was 29.8 h (ranging between 10.9 h and 
65.4 h) and no tracer-related adverse reactions 
were observed. All 10 patients were evaluated for 
immune responses to the minibody and no 
significant responses were found. This study 
showed that the T84.66 minibody was able to target 
colorectal tumors with a faster blood clearance than 
the intact mAb, however the mean residence time 
of the minibody in patients was signiﬁ  cantly longer 
than that predicted from murine models. Further 
evaluation of its biodistribution and pharmacoki-
netic properties using a longer lived radionu-
clide (such as 
111In) will be necessary in future 
studies.
Pretargeted imaging
The search of the most suitable engineered anti-
body fragments for CEA targeting and imaging 
continues. Another strategy has also been explored 
for improving the tumor-to-background con-
trast: pretargeting. Typically, either the avidin/
streptavidin-biotin pair or a bispeciﬁ  c antibody 
(BAb) is used (Gasparri et al. 1999; Sharkey et al. 
2005). A certain waiting period is needed for the 
ﬁ  rst agent to clear from the circulation and reach 
the tumor site. Sunsequently, a second agent is 
administered which will target and bind to the ﬁ  rst 
agent, thus giving excellent tumor contrast if the 
system is designed properly.
The most common strategy for tumor pretarget-
ing involves the use of the streptavidin-biotin 
recognition system (Casalini et al. 1997; Hnatowich 
et al. 1993; Karacay et al. 1997; Li et al. 2005). In 
1993, tumor localization was investigated using a 
two-step pretargeting system, in which radiola-
beled biotin was administered after streptavidin 
injection (Hnatowich et al. 1993). In the control 
group, nude mice bearing CEA-positive tumors 
(LS174T colorectal cancer) received 
111In-labeled 
anti-CEA antibody or 
111In-labeled streptavidin 
were sacriﬁ  ced at 5 h p.i. In the pretargeting group, 
the animals received unlabeled streptavidin 
followed by 
111In-labeled biotin at 3 h later. 
Because of the lower levels of labeled streptavidin 
in the liver and the blood, the tumor-to-normal 
tissue ratios were higher for 
111In-labeled strepta-
vidin than those of the 
111In-labeled anti-CEA 
antibody, although the absolute tumor accumula-
tion of administered radioactivity was lower for 
111In-labeled streptavidin. When unlabeled strep-
tavidin was administered ﬁ  rst and followed by 
111In-labeled biotin (pretargeting), the tumor uptake 
was further reduced. However, because the radio-
activity concentration in the normal tissues was 
reduced to a even greater extent, the tumor-to-
blood and tumor-to-liver ratios were 10.6 and 
2.2 respectively for the pretargeting group, 
signiﬁ  cantly higher than those for the 
111In-labeled 
anti-CEA antibody (1.5 and 0.5 respectively). 
Improvement in tissue-to-muscle ratios was also 
seen in all tissues sampled except the kidney. It 
should be noted that an intact antibody circulates 
for days in the blood with virtually no tumor 
contrast at this early time point (5 h p.i.). Most 
likely the radiolabeled antibody would have out-
performed the radiolabeled streptavidin, as well as 
the two-step pretargeting approach, at late time 
points after it has cleared from the circulation and 
accumulated more in the tumor.
In 1996, a three-step system for tumor pretarget-
ing was introduced (Magnani et al. 1996). To 
evaluate the use of pretargeted immunoscintigra-
phy in the diagnosis and follow-up of patients with 
medullary thyroid carcinoma, twenty-ﬁ  ve patients 
with histologically proven disease were enrolled 
(Magnani et al. 1996). A biotinylated anti-CEA 
mAb was injected ﬁ  rst. One day later, avidin was 
administered i.v. followed by 
111In-labeled biotin 
after another day. Six primary tumors, diagnosed 
by increased calcitonin levels, were all successfully 
imaged. Forty-seven suspected recurrences based 
on elevated blood tumor markers were detected 
and conﬁ  rmed by cytology or histology. In one 
case, SPECT imaging enabled the detection of 
small lymph nodes with diameters of 4–7 mm. 
These lesions, not considered to be neoplastic 
based on ultrasound imaging, were conﬁ  rmed to 
be neoplastic after ﬁ  ne needle aspiration. Not only 
did pretargeted immunoscintigraphy correctly 
localize primary tumors and recurrences in 442
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medullary thyroid cancer patients, false-negatives 
(when the tumor does not express high level of 
CEA therefore not detectable by radiolabeled anti-
CEA antibodies) could also potentially be avoided 
since this three-step strategy can signiﬁ  cantly 
enhance the tumor contrast, thus allowing for 
accurate detection of lesions with low CEA expres-
sion level.
This pretargeting strategy has also been used 
for radioimmunotherapy of colorectal cancer in 
mouse xenograft models (Karacay et al. 1997; 
Sharkey et al. 1997). In a recent study, the avidin-
biotin system was further optimized through the 
use of a streptavidin conjugate of the chimeric mAb 
T84.66 (Jia et al. 2007). Tumor uptake of 
111In-
labeled biotin peaked at 3.3% ID/g at 15 minutes 
p.i. Tracer clearance from the blood and normal 
organs was extremely rapid with a tumor-to-blood 
ratio of about 20:1 at 24 h p.i., thus making it a 
promising strategy for the imaging of CEA-positive 
cancers. However, since the absolute tumor uptake 
is low, this method needs to be further optimized 
for potential therapeutic applications.
One major disadvantage of the avidin/streptavidin-
biotin-based systems is that avidin/streptavidin can 
cause severe immune responses in certain cases 
(Marshall et al. 1996; Schetters 1999). Therefore, 
another method has been explored which uses a 
BAb and a radiolabeled hapten peptide (Gautherot 
et al. 1997; Gautherot et al. 1999; Gautherot et al. 
2000; Karacay et al. 2000). The immunogenicity 
of BAbs can be eliminated by the use of humanized 
antibody fragments (Boerman et al. 2003; Chang 
et al. 2002). Initially, BAbs were developed as 
tumor targeted delivery agents for certain drugs. 
BAbs can be generated as small, multivalent, anti-
gen-binding fragments with improved pharmaco-
kinetic properties than the primary antibodies, 
meanwhile also capable of binding to a versatile 
bivalent hapten peptide which contains an imaging 
label (Chang et al. 2002; Rossi et al. 2005).
A humanized bispeciﬁ  c fusion protein of the 
two Fv portions from an anti-CEA mAb (hMN-14; 
labetuzumab) and another antibody, which 
recognizes an inert hapten peptide (histamine-
succinyl-glycine; HSG), was explored for local-
izing 
99mTc-labeled HSG to human colonic tumors 
in a xenograft model (Sharkey et al. 2005; Sharkey 
et al. 2003). The results based on this pretarget-
ing strategy were compared to the data obtained 
from the clinically used CEA-Scan (Fig. 3). 
Tumors as small as 0.15 g were detected within 1 h 
of  
99mTc-HSG administration, with tumor-to-blood 
ratios signiﬁ  cantly increasing over time (10:1 and 
100:1 at 1 and 24 h p.i., respectively). Comparing 
with CEA-Scan, this pretargeting strategy increased 
the tumor uptake by ten-fold (to ∼20% ID/g) under 
optimal conditions. Recently, it was shown that 
pretargeting could localize tumors in the lungs 
within 1.5 h p.i. of the radiolabeled HSG peptide, 
while 
18F-FDG PET failed to detect the tumor 
(Goldenberg et al. 2008). Autoradiography dem-
onstrated selective tumor targeting within the 
lungs, including metastases less than 0.3 mm in 
diameter. It was concluded that BAb-based pretar-
geting is highly specific for imaging micro-
metastatic lesions and may thus provide a 
complementary method to 
18F-FDG PET in the 
clinical setting.
The major advantage of SPECT imaging is that 
it can be used for simultaneous imaging of mul-
tiple radionuclides since the gamma rays emitted 
from different radioisotopes can be differentiated 
based on the energy (Berman et al. 1994). Thus, 
SPECT can potentially allow for simultaneous 
detection of multiple biological events with mul-
tiple isotopes, which is not possible with PET. 
However, dual-isotope SPECT imaging has not 
been widely used and it is unclear whether simul-
taneous dual-isotope imaging can offer signiﬁ  cant 
advantages over single radionuclide imaging. In 
the past, gamma cameras and SPECT imaging 
systems were much more readily accessible than 
PET systems (Blake et al. 2003). Therefore, the 
number of literature reports on SPECT imaging of 
CEA far exceeded the number of PET studies, 
which will be the focus of the remaining text.
PET Imaging of CEA Expression
PET has much higher sensitivity than SPECT, 
typically 10% and 0.1% respectively (Gambhir, 
2002). Due to the high cost and limited availability, 
PET imaging was not employed for CEA imaging 
until the late 1990s. With the continuous develop-
mental effort, state-of-the-art small animal PET 
scanners can have spatial resolution (1 mm) 
comparable to SPECT and they are also becoming 
increasingly widely available (Chatziioannou, 
2005; Stickel et al. 2007). Therefore, PET imaging 
of various molecular cancer markers has ﬂ  ourished 
over the last several years (Cai and Chen, 2007a; 
Cai and Chen, 2008; Cai et al. 2008a; Cai et al. 
2008b). Similar to SPECT imaging, the PET 443
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CEA-Scan
Pretargeting
99mTc-HSG
2min 20min 60min
Tumor cell
CEA CEA
CEA
MN14 MN14
MN14 MN14
CEA
BAb BAb
679 679
Step 1
HSG HSG
99mTc
Step 2
Radiotracer
divalent HSG-
hapten-peptide
Figure 3. Pretargeted SPECT imaging of CEA expression. A) The mechanism of bispeciﬁ  c antibody-based pretargeting. B) In vivo distribution 
kinetics of CEA-scan (a 
99mTc-labeled anti-CEA Fab’ fragment), 
99mTc-labeled HSG peptide following a pretargeted bispeciﬁ  c antibody and 
99mTc-labeled HSG peptide alone in LS174T tumor-bearing mice. T: tumor; H: heart; K: kidney; UB: urinary bladder. Adapted from (Sharkey 
et al. 2005).444
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isotopes with short half-lives are more suitable for 
labeling smaller molecules while the isotopes with 
longer half-lives are needed for antibody labeling 
to match its relatively long circulation half-life.
Positron emitter labeled antibodies
Various PET isotopes have been used to label mAbs 
for radioimmunoPET imaging of cancer. MAbs 
directed against CEA was labeled with 
124I, a 
positron emitter with a half-life of 4.2 days 
(Westera et al. 1991). Mice xenografted with CEA-
positive tumors were visualized by PET imaging 
after injection of the 
124I-labeled mAb. Comparison 
of the PET and biodistribution studies indicated 
that radioimmunoPET could provide more accurate 
radiation dosimetry estimation for radioimmuno-
therapy, in addition to potentially more precise 
diagnosis.
Other positron emitting isotopes such as 
76Br 
(t1/2: 16.0 h) (Lovqvist et al. 1999; Lovqvist et al. 
1995; Lovqvist et al. 1997a) and 
64Cu (t1/2: 12.7 h) 
(Li et al. 2008) were also used to label anti-CEA 
antibodies. For the 
76Br-labeled anti-CEA mAb, 
tumor sites could be readily identiﬁ  ed by PET 
imaging from 46 h p.i. onwards. Interestingly, the 
concentration of 
76Br in the tumor, blood and most 
normal tissues was higher than that of 
124I at all 
time points. It was suggested that this phenomenon 
was mainly due to the catabolism of radiolabeled 
mAb which resulted in free radiohalogen: 
76Br was 
persistently retained in the tumor while 
124I was 
rapidly excreted. When compared with 
18F-FDG 
and 
11C (t1/2: 20.4 min) labeled methionine, the 
76Br-labeled mAb was superior to both agents in 
subcutaneous tumor models. Further, 
76Br-labeled 
mAb and 
18F-FDG were equally successful for the 
identification of liver metastases, both out-
performed SPECT imaging with radiolabeled anti-
CEA mAbs (Lovqvist et al. 1997b).
Positron emitter labeled 
antibody fragments
Antibody fragments, when designed and radiola-
beled properly, are more advantageous than intact 
antibodies for imaging applications. An early 
study investigated whether the Fab’ fragment 
(termed “CEA-Scan” when labeled with 
99mTc) 
could be labeled with a positron-emitting nuclide: 
94mTc (t1/2: 52.5 min) (Grifﬁ  ths et al. 1999). “Instant 
kits” containing the lyophilized Fab’ fragment of 
an anti-CEA IgG (arcitumomab) were reconstituted 
with 
94mTc. Radio-analyses of the 
94mTc-labeled 
Fab’ fragment indicated that 
94mTc could be readily 
incorporated in a similar fashion as 
99mTc-labeling. 
Although it was suggested that 
94mTc-labeling 
would enable the investigation of this agent for 
PET imaging of cancer, no further preclinical or 
clinical research was reported regarding its tumor 
targeting capability in vivo.
To the best of our knowledge, no PET imaging 
of tumor CEA expression with scFvs was reported 
due to the poor tumor targeting characteristics of 
this class of antibody fragments (Holliger and 
Hudson, 2005; Wu and Senter, 2005). To date, PET 
imaging of CEA is primarily based on minibodies 
or diabodies (Cai et al. 2007d; Grifﬁ  ths et al. 2004; 
Sundaresan et al. 2003; Wu et al. 2000). An anti-
CEA minibody was ﬁ  rst labeled with 
64Cu for PET 
imaging of cancer (Wu et al. 2000). DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid), the most commonly used macrocyclic chela-
tor for labeling a variety of radiometals such as 
64Cu (Cai et al. 2006a; Cai et al. 2006c; Liu et al. 
2007), was also used in this study for 
64Cu-labeling. 
In vivo distribution of the tracer was evaluated in 
athymic mice bearing both LS174T colorectal 
carcinoma (CEA-positive) and C6 rat glioma 
(CEA-negative) tumors. Five hours after injection 
of the 
64Cu-labeled anti-CEA minibody, microPET 
imaging showed signiﬁ  cantly higher uptake in the 
CEA-positive tumor (17.9 ± 3.8% ID/g) than the 
control C6 tumor (6.0 ± 1.0% ID/g). Signiﬁ  cant 
radioactivity uptake was also seen in liver which 
is likely attributed to two major factors: the retic-
uloendothelial system uptake of the minibody due 
to its relatively large size (80 kDa) and the possible 
trans-chelation of  
64Cu (Cai et al. 2007b; Cai and 
Chen, 2007b; Cai and Chen, 2008).
124I- or 
64Cu-labeled anti-CEA diabody was 
initially evaluated in mice xenografted with 
LS174T tumors (Olafsen et al. 2004a; Sundaresan 
et al. 2003). For the 
124I-labeled diabody, PET imag-
ing showed speciﬁ  c localization to CEA-positive 
tumors and low activity elsewhere in the mice 
(Sundaresan et al. 2003). Tumor-to-background 
ratios were 4.0 and 10.9 at 4 and 18 h, respectively. 
At 18 h p.i., the radioactivity in the normal organs 
(including the liver and kidneys) were nearly fully 
cleared, leaving only the CEA-positive tumors with 
excellent contrast. Tumors as small as 11 mg 
(3 mm in diameter) could be imaged by the 
124I-labeled anti-CEA diabody, which signiﬁ  cantly 
out-performed 
18F-FDG PET. For the 
64Cu-labeled 445
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anti-CEA diabody, the tumor-to-background ratio 
was 4.6 at 18 h p.i. (Olafsen et al. 2004b), signiﬁ  -
cantly lower than the 
124I-labeled version. Further, 
possible trans-chelation of 
64Cu also resulted in 
elevated liver activity (19.4%ID/g at 4 h p.i.).
124I and 
64Cu each has several disadvantages for 
PET imaging applications. For example, both iso-
topes have low positron efﬁ  ciency (25%) which 
resulted in low signal intensity. The relatively long 
half-lives of the two isotopes may not be optimal/
necessary for the labeling of diabodies since 
diabodies typically clear quite rapidly from the 
circulation. For clinical translation, 
18F-labeled 
diabody is potentially more suitable since 
18F offers 
the advantages of broad availability, a high positron 
yield (nearly 100%) and a short half-life ideal for 
routine clinical use.
An imaging ﬁ  gure of merit (IFOM) analysis, a 
measure of how rapidly a statistically signiﬁ  cant 
tumor image can be acquired (Williams et al. 2001), 
was performed for combinations of different radio-
nuclides across various engineered antibody frag-
ments (scFv, diabody, minibody, F(ab’)2 and intact 
antibody) based on murine biodistribution data. This 
analysis predicted that diabody should provide the 
best vehicle for 
18F and optimal imaging should occur 
at 1–2 h after injection (Williams et al. 2001).
Such prediction was conﬁ  rmed by a recent study 
(Cai et al. 2007d). An anti-CEA diabody was 
labeled with 
18F which gave high-contrast PET 
images of tumors, with tumor-to-normal tissue 
ratios as high as 6.2 at 4 h p.i. (Fig. 4). Most impor-
tantly, the tumor contrast was sufﬁ  ciently high to 
allow for PET imaging as early as 1 h p.i. The 
choice of 
18F as the best PET radionuclide for 
diabodies meets the needs and experience of PET 
clinicians who are familiar with the equipment used 
for and the interpretation of conventional 
18F-FDG 
PET scans (Shively, 2007). It is obvious that imag-
ing agents that require a patient to stay overnight 
or to return on the following day dramatically 
increase the cost of the procedure and patient 
inconvenience. Because of the slow clearance of 
intact antibodies, antibody-based PET or SPECT 
scans often require the scans be performed at up to 
3 days after tracer injection. This proof-of-principle 
study clearly suggested the enormous potential of 
18F-labeled diabodies for radioimmunoPET imag-
ing in the clinic. Upon further improvement in the 
immunoreactivity and radiolabeling yield, 
18F and 
diabody may prove to be the optimal combination 
for clinical diagnosis of cancer.
Pretargeted PET imaging
BAb-based pretargeting strategy has been applied 
for PET imaging. A peptide, DOTA-D-Tyr-
D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2, was 
4% ID/g
0% ID/g
30 min 1 h 2 h 4 h
C6
CEA –
CEA +
LS174T
Figure 4. Dynamic small-animal PET scans of LS174T human colorectal (CEA-positive) tumor-bearing mice and C6 rat glioma (CEA-negative) 
tumor-bearing mice after inejction of a 
18F-labeled anti-CEA diabody. Coronal whole-body slices that contained the tumors (arrows) are 
shown. Adapted from (Cai et al. 2007d).446
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synthesized and labeled with 
124I (McBride et al. 
2006). Pretargeted imaging with the 
124I-labeled 
peptide was tested in nude mice bearing LS174T 
tumors that were ﬁ  rst injected with a BAb that 
recognizes both CEA and HSG. Comparisons were 
performed between animals injected with a 
124I-labeled anti-CEA Fab’ fragment, 
18F-FDG, the 
same peptide labeled with 
111In and pretargeted 
with the BAb, or the 
124I-labeled peptide alone. It 
was found that the 
124I-labeled peptide cleared 
quickly from the blood with no evidence of tumor 
targeting. When pretargeted with the BAb, tumor 
uptake of the tracer increased by 70-fold. The 
efﬁ  cient and rapid clearance of the tracer from 
normal tissues enabled clear visualization of the 
tumor within 1–2 h p.i. Tumor uptake measured at 
necropsy was found to be 3- to 15-fold higher than 
that of the 
124I-labeled Fab’ fragment and the 
tumor-to-blood ratios were 10- to 20-fold higher. 
Tumor visualization with 
18F-FDG PET at approx-
imately 1.5 h p.i. was also quite satisfactory. 
However, the substantially higher uptake of 
18F-FDG in several normal tissues made image 
interpretation in the pretargeted animals far less 
ambiguous than with 
18F-FDG PET.
Subsequently, it was reported that this BAb-
based pretargeting approach not only signiﬁ  cantly 
enhanced tumor-to-normal tissue ratios but also 
provided higher signal intensity in the tumor 
(Sharkey et al. 2007). With anti-CEA BAb-based 
pretargeting, it was possible to visualize micro-
metastases of colonic cancer as small as 0.1 to 
0.2 mm in diameter, whereas 
18F-FDG PET failed 
to localize these lesions in a nude mouse model. 
68Ga (t1/2: 68 min), a PET isotope that can be pro-
duced by generators, has also been reported for 
pretargeted imaging of CEA expression in tumor 
models (Grifﬁ  ths et al. 2004).
Summary
A wide variety of strategies have been explored for 
CEA-targeted cancer imaging, including the use of 
intact antibodies, a number of differently sized anti-
body fragments and pretargeting strategies (Table 1). 
For antibody- and antibody fragment-based imaging, 
it appears that intermediate sized fragments are the 
optimal choices for imaging applications. In par-
ticular, diabodies are very promising agents since 
they can retain the high avidity of the original intact 
antibody while at the same time exhibiting short 
circulation half-lives. BAb-based pretargeting 
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method can be useful for both CEA imaging and 
CEA-targeted immunotherapy. For diagnostic pur-
poses, BAb-based pretargeted imaging was reported 
to be capable of outperforming 
18F-FDG PET, the 
current “gold standard” for clinical cancer diagnosis 
and staging. However, pretargeting strategy still has 
a long way to go before it can be widely used for 
therapeutic applications. Although it can give excel-
lent tumor contrast in many cases, the absolute 
uptake level in the tumor is still far less that that of 
radiolabeled antibodies. Therefore, radiolabeled 
intact antibodies are still the best choices for radio-
immunotherapy of CEA-positive tumors.
Translating novel anti-cancer agents from bench 
to bedside is typically time-consuming and quite 
expensive (DiMasi et al. 2003). Multiple steps in 
preclinical development, especially the investiga-
tional new drug (IND)-directed toxicology, 
signiﬁ  cantly slowed down this process (Cai and 
Chen, 2006; Cai et al. 2006b). Development of 
protein-based therapeutics, such as those targeting 
CEA, is even more difﬁ  cult and expensive compar-
ing to traditional small molecule-based drugs. Not 
only are proteins relatively difﬁ  cult to manufacture 
in large quantities, good laboratory/manufacturing 
practice (GLP/GMP) compliance is also much more 
technically challenging. Currently, a vast number 
of new anti-cancer therapies are in preclinical and 
clinical testing. Whether antibody- and/or antibody 
fragment-based CEA imaging and/or therapy is cost 
effective and whether it can be included in the 
clinical regimens for various cancers is still debat-
able. Development of peptide-based tracers should 
be explored for CEA imaging in the future.
A signiﬁ  cant portion of the preclinical CEA 
imaging studies used the LS174T colorectal cancer 
xenograft model, which has very high level of CEA 
expression. They may not truly reﬂ  ect the clinical 
situation where CEA expression is quite heterog-
enous, not only between patients but also between 
the different lesions in the same patients. Studies 
in other more clinical relevant orthotopic or trans-
genic mouse models will more closely mimic the 
clinical situation, thereby providing more clinically 
relevant ﬁ  ndings. Another aspect not well studied 
is the quantitative imaging of CEA expression in 
vivo. Although it is generally assumed that 
noninvasive imaging results correlate with the 
target expression level, such assumption has not 
been extensively validated. In most reports, two 
tumor models are used where one acts as a positive 
control and the other as a negative control. 
Quantitative correlation between the target 
expression level in vivo and the noninvasive PET 
imaging data is rare (Cai et al. 2007a; Cai et al. 
2007c; Zhang et al. 2006). Such correlation is 
critical for future treatment monitoring applications, 
as it would be ideal to be able to monitor the changes 
in the target expression level quantitatively, rather 
than qualitatively, in each individual patient.
Interestingly, a signiﬁ  cant portion of the clinical 
data regarding CEA imaging comes from early 
studies more than 10 years ago, although at that 
time the term “molecular imaging” has not been 
widely spread across the scientiﬁ  c community. The 
explosion of molecular imaging research over the 
last decade is partially, if not mostly, due to 
the increasingly wider availability of scanners 
dedicated to small animal studies. However, with 
an overwhelming number of animal studies reported 
every week, clinical translation has become more 
and more difﬁ  cult in the United States due to many 
regulatory constraints. Many scientiﬁ  c societies 
have recently tried to work with the regulatory 
agencies (most notably the FDA) in order to allevi-
ate the prohibitively expensive requirements before 
initial clinical evaluation of molecular imaging 
agents, especially PET/SPECT agents since they 
are administered at doses many orders of magnitude 
below the pharmacologically active level. To date, 
most of the imaging probe development comes 
from academic institutions. Signiﬁ  cant involvement 
from clinicians, pharmaceutical industries, govern-
ment agencies are needed to allow for rapid ﬁ  rst-
in-human evaluations and subsequent clinical trials. 
The molecular imaging ﬁ  eld has grown extremely 
fast over the last decade and the value of molecular 
imaging in drug development and cancer patient 
management is getting more widely accepted 
(Rudin and Weissleder 2003; Willmann et al. 2008). 
It is expected that in the foreseeable future molec-
ular imaging will be routinely applied in clinical 
trials and cancer patient management.
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